U.S. Markets close in 4 hrs 52 mins

Champions Oncology, Inc. (CSBR)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.53+0.04 (+1.61%)
As of 10:10AM EDT. Market open.
People also watch
CGNTEYEGZSANCLRBCRTN

Champions Oncology, Inc.

One University Plaza
Suite 307
Hackensack, NJ 07601
United States
201-808-8400
http://www.championsoncology.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees68

Key Executives

NameTitlePayExercisedAge
Dr. Ronnie Morris M.D.Chief Exec. Officer and Director15.06kN/A51
Dr. David Sidransky M.D., Ph.D.Founder, Lead Director and Scientific AdvisorN/AN/A57
Mr. David Barry MillerVP of Fin.221.88kN/A48
Dr. Philip P. Breitfeld M.D.Chief Scientific & Innovation Officer and DirectorN/AN/A64
Mr. Mark WeinsteinChief Information OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient’s tumor for the purpose of identifying useful drugs. In addition, the company offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that use vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. Further, it provides a bank of tumors that are acquired, collected, processed, validated, and stored for the use in TOS. The company markets its products through Internet, word of mouth, and a network of sales force. It serves patients, physicians, and drug development companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. is headquartered in Hackensack, New Jersey.

Corporate Governance

Champions Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.